国产创新药对外授权交易频现大单，板块投资机会受关注。日前，恒生港股通创新药指数宣布修订编制 方案，明确剔除CXO公司，修订规则将于8月11日生效，该指数将成为ETF跟踪的指数中首批"纯度"达 100%的创新药指数。作为市场上唯一跟踪该指数的ETF，恒生创新药ETF（159316）已连续14个交易日 获净流入，产品份额连创新高，可助力投资者一键布局前沿创新药企。 近期，我国多家创新药公司达成大额专利授权交易。7月30日，石药集团与Madrigal达成全球授权协 议，含1.2亿美元预付款和最高19.55亿美元里程碑付款，同日中国生物制药公告全资附属公司与默沙东 LM-299/MK-2010项目合作进展顺利，将于近期收到3亿美元技术转移里程碑付款。7月28日，恒瑞医药 公告与英国制药巨头葛兰素史克达成一项总潜在金额达125亿美元的License out合作，涵盖12个创新药 项目。 A股港股午后均大幅反弹，港股创新药板块震荡上行，截至14:38，恒生港股通创新药指数上涨0.3%， 云顶新耀上涨9.2%，晶泰控股上涨6.8%，四环医药上涨4.6%，恒生创新药ETF（159316）盘中成交额 超4亿元。 ...

Investment Rating - The report maintains a "Buy" rating for several companies in the biotechnology sector, including Legend Biotech (LEGN US), and others like 3SBio (1530 HK), Innovent Biologics (1801 HK), and more, indicating a positive outlook for these stocks [7]. Core Insights - The upcoming centralized procurement of biosimilars in mainland China is expected to impact multiple major products, with the first round of information collection already initiated [2]. - The report emphasizes that the impact of this procurement on company performance and product sales will likely be felt starting in 2026, as the process is expected to take longer due to the novelty of biosimilar procurement in China [2]. - Companies such as China Biologic Products, Innovent Biologics, and Hengrui Medicine are highlighted as key players with multiple products involved in the procurement process, warranting close attention to pricing and allocation results [2][3]. - The report suggests that the impact on innovative drugs will be limited, as the products involved in the procurement are off-patent and already have competing biosimilars [2]. Summary by Sections Section: Centralized Procurement - The centralized procurement for biosimilars is officially starting, with a focus on eight monoclonal antibody products [2]. - The information collection phase is expected to last 1-2 months, with a longer timeline anticipated for rule formulation and final product inclusion [2]. Section: Company Focus - Key companies to watch include China Biologic Products, Innovent Biologics, and Hengrui Medicine, with respective products in the procurement process [2]. - The report recommends monitoring the pricing and allocation outcomes closely for these companies [2]. Section: Innovative Drugs - The report indicates that the eight monoclonal antibodies involved in the procurement are already off-patent and have existing biosimilars, suggesting limited impact on innovative drugs still under patent [2]. - Continuous attention is advised for the upcoming national medical insurance negotiations and the establishment of commercial insurance innovative drug directories [2].

Market Overview - The A-share market opened lower on August 4, but the Shanghai Composite Index managed to turn positive by the time of reporting [1] - The Hong Kong market also saw the Hang Seng Index and Hang Seng Tech Index open lower but later turned positive [4] Sector Performance - Gold and media sectors showed strength against the market trend, while most sectors like CPO, computing power, and AI experienced pullbacks [2] - Banking stocks collectively strengthened during the session, with notable gains from Qingdao Bank (up 4.16%), Shanghai Pudong Development Bank (up 3.25%), and others [2][3] Banking Sector Highlights - Qingdao Bank led the gains among banking stocks with a price of 5.01, while other banks like Agricultural Bank of China and Industrial and Commercial Bank of China also saw increases [3] Data Center and AI Sector - The data center power concept saw a rise, with Jianghai Co. hitting the daily limit and Kexin New Energy rising over 10% [6] - The rapid development of the AI industry is expected to enhance the penetration of HVDC technology in data centers, presenting growth opportunities for companies with mature HVDC products [8] Robotics Sector - The robotics sector remains strong, with companies like Zhongma Transmission and Dongjie Intelligent hitting daily limits [8] - The World Robot Conference scheduled for August 8-12 in Beijing will showcase over 1,500 exhibits from more than 200 domestic and international robotics companies [8] Gold Sector in Hong Kong - Gold stocks in Hong Kong showed significant gains, with Tongguan Gold rising over 6% and Chifeng Gold up over 5% [11] - The weak U.S. non-farm payroll data for July, which added only 73,000 jobs, has raised expectations for a potential interest rate cut by the Federal Reserve, boosting demand for safe-haven assets [11] Semiconductor Sector - The semiconductor sector also performed well, with Huahong Semiconductor rising nearly 5% and SMIC up over 2% [11] - The global silicon wafer shipment volume is projected to increase by 9.6% year-on-year in Q2 2025, indicating a positive trend in the semiconductor industry [11]

8月4日，中国生物制药(01177)盘中下跌2.19%，截至10:03，报7.16元/股，成交3.03亿元。 截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。 本文源自：金融界 作者：行情君 中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生 产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗 领域具有优势。公司自从2000年上市以来，在MSCI全球标准指数、恒生指数等多个指数中成为成分 股，连续六年入选《制药经理人》的"全球制药企业TOP50"，核心企业正大天晴药业集团、北京泰德制 药股份有限公司多年位列中国医药工业企业百强榜，公司产品收入占比逐年提升。 ...

转自：证券时报 人民财讯8月4日电，恒生指数开盘跌0.31%，恒生科技指数跌0.66%。中国生物制药跌超3%，比亚迪股 份跌超2%。 ...

Market Overview - The Shanghai Composite Index fell by 0.36%, the Shenzhen Component Index decreased by 0.53%, and the ChiNext Index dropped by 0.66% [1][3] - The A-share market saw 765 stocks rise, 477 remain flat, and 4173 decline [4] Precious Metals Sector - The precious metals sector showed strength against the market trend, with Chifeng Jilong Gold Mining Co. rising nearly 4% and other companies like Western Gold, Xiaocheng Technology, and Shandong Gold increasing by over 3% [1][5] - A detailed list of notable gainers includes: - Chifeng Jilong Gold: +3.98% - Xinyu Gold: +3.78% - Xiaocheng Technology: +3.74% - Shandong Gold: +3.46% - Hunan Gold: +1.86% [2] AI Industry - The AI industry chain experienced a general pullback, with significant declines in CPO and AI application concepts [3] Hong Kong Market - The Hang Seng Index opened down by 0.31%, with the Hang Seng Tech Index falling by 0.66% [5][6] - Pharmaceutical stocks continued to adjust, with companies like China Biopharmaceutical and Guotai Junan International both dropping over 3% [5] Central Bank Operations - The central bank conducted a 7-day reverse repurchase operation amounting to 544.8 billion yuan at an interest rate of 1.40% [7] Currency Exchange - The central bank set the RMB to USD middle rate at 7.1395, an increase of 101 basis points from the previous day [8]

Market Overview - The Shanghai Composite Index closed at 3559.95, down 0.37% for the week, with a trading volume of 684.645 billion CNY[18] - The average daily trading volume for the entire A-share market was 1.81 trillion CNY, a decrease of 39 billion CNY from the previous week[21] Market Style Performance - The only index that saw a gain this week was the Wind Micro Index, which increased by 1.46%[25] - The CSI 500 index fell by 1.37%, while the CSI 300 index dropped by 1.75%[25] Participant Performance - The active capital holding index outperformed, with the private equity heavy index declining only 0.65% compared to the overall market decline of 1.09% for the Wind All A Index[33] Market Sentiment - The margin trading balance increased to over 1.98 trillion CNY, reaching a new high for the year[36] - The number of stocks hitting the daily limit up or down remained relatively stable, indicating a steady market sentiment[36] Sector Performance - Strong sectors included innovative pharmaceuticals and optical modules, with significant partnerships announced in the industry[51] - The report highlighted the importance of AI applications, particularly following the approval of a government initiative to implement "AI+" actions[51] Future Outlook - Upcoming events include product launches in the TMT sector and significant industry conferences, which may influence market trends[54] - The report emphasizes a focus on active domestic circulation, technological self-reliance, and expanding openness in the market[55]

Market Overview - The average daily trading volume of the entire A-share market was 1.81 trillion CNY, a slight decrease of 39 billion CNY compared to the previous week[8] - The Shanghai Composite Index fell by 0.94% this week, while the ChiNext Index decreased by 0.74%[12] Market Style Performance - The small-cap index (WIND Micro Index) rose by 1% this week, showing relative strength compared to large-cap indices[12] - Growth stocks outperformed value stocks, with the relative advantage of growth stocks oscillating in positive territory over the past 30 trading days[18] Participant Performance - Active funds showed relative superiority this week, with the National Team Index declining by 1.92% and the Social Security Heavyweight Index down by 1.83%[22] - The overall A-share market saw a decline of 1.09% this week, with the market sentiment index showing a slight increase[21] Market Sentiment - The margin trading balance increased to over 1.98 trillion CNY, reaching a new high for the year[25] - The number of stocks hitting the daily limit up was 62, while those hitting the limit down was 12, indicating relatively stable market sentiment[25] Sector Performance - The report highlights strong performance in sectors such as innovative pharmaceuticals and AI applications, with significant partnerships announced in the industry[41] - The report also notes the importance of technology self-reliance and expanding openness in the context of ongoing geopolitical tensions[43]

证券研究报告|海外策略周报 [Table_Date] 2025 年 8 月 2 日 [Table_Title] 本周全球多数市场回调，周内波动加大 1[Table_Title2] --海外策略周报 [Table_Summary] 全球市场一周主要观点:本周全球多数市场出现明显的回调，周 内多个交易日波动加大。本周美股三大指数回调，由于是在周 五公布的非农数据不及预期之后，美股出现明显调整。目前 TAMAMA 科技指数市盈率仍有 35.5，市盈率处于高于 35 以上 的偏高位区间；费城半导体指数市盈率仍有 50.4，仍然处于 50 以上的高位区间；美国科技股权重占比较大的纳斯达克指数的 市盈率仍然有 41.2，处于高于 40 的偏高位阶段，由于美股科技 股估值较高存在进一步消化估值的趋势，以及美股大型科技巨 头的新一轮科技风口还需等待，叠加美国经济和贸易等方面政 策的不确定性影响，美股科技股仍然容易出现调整；纳斯达克 指数、费城半导体指数和 TAMAMA 等美股科技指数仍然中期 维度仍然容易出现进一步回调。目前标普 500 席勒市盈率仍有 38，仍然大幅高于历史中位数和平均数。由于美国经济和贸易 政策的不确定性 ...

Core Viewpoint - The company has made significant progress in its innovative transformation, focusing on drug development in oncology, liver disease/metabolism, respiratory, and surgical/pain management, with multiple pipelines showing potential for overseas licensing [1][2][3] Group 1: Innovation and R&D Investment - The company has increased its R&D investment to 17.6% of revenue in 2024, up from 9.9% in 2019 [2] - By the end of 2024, the company has received approval for 17 innovative drugs, with innovative product revenue accounting for 42% of total revenue, compared to 11% in 2015 [2] - The company has averaged over 3 License in transactions per year from 2019 to 2024, enhancing the richness of its innovative drug pipeline [2] Group 2: Product Pipeline and Market Potential - The oncology pipeline includes key products such as Anlotinib, which has received approval for 9 indications and has 4 additional indications submitted for NDA [3] - The company is advancing several promising products, including TQB2102 (HER2 dual antibody ADC) and TQC3721 (PDE3/4 inhibitor), which have significant potential for overseas licensing [3] - The company’s biosimilar drugs have a combined market capacity of 240 billion yuan in 2024, indicating strong growth potential [3][4] Group 3: Financial Projections and Valuation - The company expects revenue growth of 11.4%/10.5%/9.6% for 2025E/26E/27E, with adjusted net profit growth of 12.2%/11.5%/10.5% [4] - The target price is set at 9.40 HKD based on a 10-year DCF model, corresponding to a 37x adjusted PE for 2026 [4]